b cell lymphoma การใช้

• Her team notably elucidated the difference between T cell and B cell lymphomas.
• Over-expression of miR-155 leads to B cell lymphomas in mice ( reviewed in
• In another recent study, Golub and colleagues predicted the prognosis of people with diffuse large B cell lymphoma.
• When they occur in an HIV-infected patient, KS and aggressive B cell lymphomas confer a diagnosis of AIDS.
• A third study investigates CPI-1205, another small molecule EZH2 enzyme inhibitor, as an interventional treatment of B cell lymphoma.
• It was awarded orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
• Diffuse large B cell lymphomas are the most common subtype of NHL, constituting about 30 to 40 % of adult NHLs.
• In B cells in the lymph nodes, AID causes mutations that produce antibody diversity, but that same mutation process leads to B cell lymphoma.
• A third member of this family  RHBDD1  cleaves Bcl-2-interacting killer ( proapoptotic member of the B cell lymphoma 2 ( Bcl-2 ) family.
• These cancers, known as B cell lymphomas, retain many B-cell properties including, in at least some cases, that of displaying the usual BLyS receptors on their surface.
• Chronic lymphocytic leukemia may transform into Richter's syndrome, the development of fast-growing diffuse large B cell lymphoma, prolymphocytic leukemia, Hodgkin's lymphoma, or acute leukemia in some patients.
• High-grade B cell lymphomas such as Burkitt's lymphoma, Burkitt's-like lymphoma, diffuse large B-cell lymphoma ( DLBCL ), and primary central nervous system lymphoma present more often in HIV-infected patients.
• EZH2, a histone-lysine N-methyltransferase and the functional enzymatic component of PRC2, encoded by the EZH2 gene, is a popular point of study in the treatment of B cell lymphoma.
• Follicular lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, B-cell chronic lymphocytic leukemia, peripheral T-cell lymphoma, and natural killer cell lymphoma have also been reported to affect the orbit.
• Products about to hit the market include a bioengineered antibody for non-Hodgkin's B cell lymphoma, developed by IDEC Pharmaceuticals in San Diego and co-marketed with South San Francisco-based Genentech Inc.
• In some patients, the malignant cell clone can become the dominant proliferating cell type, leading to frank lymphoma, a group of B cell lymphomas occurring in immunosuppressed patients following organ transplant.
• In 2010 administration of lymphocytes genetically engineered to express a chimeric antibody receptor ( CAR ) against B cell antigen CD19 was shown to mediate regression of an advanced B cell lymphoma.
• The second phase will determine the safety and activity of E7438p in EZH2 mutation positive subjects with histologically confirmed diffuse large B cell lymphoma Grade 3 follicular lymphomas with relapsed or refractory disease.
• The WHO 2008 update classifies grades 1 and 2 now as low grade follicular lymphoma, grade 3A as high grade follicular lymphoma, and grade 3B as Diffuse Large B Cell Lymphoma ( DLBCL ).
• Some anti-tumor responses have been reported in patients with B cell lymphoma ( treated with alfaCD20-CD3zeta CAR-modified T cells ) and some neuroblastoma patients ( treated with ScFv-CD3zeta CARTs ) reported partial response, stable disease and remission.